Finanzen von Shuttle Pharmaceuticals Holdings Inc (SHPH)SHPHShuttle Pharmaceuticals Holdings Inc

Evaluating the bottom line, Shuttle Pharmaceuticals Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -326.36%, provide a clear picture of how effectively SHPH converts its operational activities into shareholder value.

In the context of the broader market, SHPH competes directly with industry leaders such as OGEN and ONCO. With a market capitalization of $3.64M, it holds a leading position in the sector. When comparing efficiency, SHPH's gross margin of N/A stands against OGEN's N/A and ONCO's 25.13%. Such benchmarking helps identify whether Shuttle Pharmaceuticals Holdings Inc is trading at a premium or discount relative to its financial performance.

SHPH has shown a consistent negative net income, with the latest figures indicating a loss of 2,152,471 USD in Q1 2026. The current ratio is low at 0.30, suggesting potential liquidity issues. Despite these challenges, the company is positioning itself in a rapidly growing market.